SOURCE: Symbollon Pharmaceuticals, Inc.

Symbollon Pharmaceuticals, Inc.

January 21, 2010 08:26 ET

Woman's Breast Health Supplement, IoGen™, Available to Public in February From Symbollon Pharmaceuticals

MEDFIELD, MA--(Marketwire - January 21, 2010) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) ( has announced today that the retail launch of IoGen™, its dietary supplement for women's breast health, will commence in February. IoGen™ is the first dietary supplement formulated to promote breast health for women. Initially, the Company plans to market IoGen™ through its own retail web site, which is currently being developed by Atech Solutions. This rapid launch schedule was made possible when the Company reacquired the significant IoGen™ finished goods inventory previously purchased by its former distributor. In preparation of the launch, Symbollon has partnered with ProLog Logistics (, a state-of-the-art fulfillment center with a complete customer service support division.

"We are moving very quickly to prepare the IoGen™ product launch," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "We recently repurchased the IoGen finished goods inventory from our previous distributor. This significant inventory will advance our expected retail launch of IoGen™ by months. By partnering with Atech Solutions for the web site development and ProLog Logistics for complete state-of-the-art fulfillment and customer service needs, we believe that we will provide women looking to improve their breast health with a responsive and customer focused buying experience. Making this important female health product available to women is an important first step in helping improve the lives of millions of women concerned with their overall breast health."

Symbollon Pharmaceuticals, Inc. Resources:

--  Corporate Profile:
--  FAQ:
--  Technology Overview:

About ProLog Logistics

Since its inception in 1996, ProLog Logistics has remained focused on delivering high-quality and cost-effective operational out-sourcing solutions. Utilizing two state-of-the-art distribution facilities, coupled with a centralized call center, ProLog is ideally positioned to meet the operational needs of its clients.

About Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA)

Symbollon is a specialty biotechnology company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. For more information about Symbollon, please visit the company's website at

Forward Looking Statement: This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercialize IoGen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) management and the Board of Directors will be able to maximize shareholder value by leveraging the Company's proprietary technology, and (v) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Symbollon Pharmaceuticals, Inc.
    Alex Johnston
    Investor Relations

    Premier Media Service Inc.
    Kelly Black